Pharmacovigilance and Drug Safety Software Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Pharmacovigilance 
and Drug Safety Software 
Market Research and 
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " P h a r m a c o v i g i l a n c e  a n d  D r u g  S a f e t y  
S o f t w a r e  M a r k e t :  G l o b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  
2 0 2 4 - 2 0 3 2 , "  t h e  g l o b a l  p h a r m a c o v i g i l a n c e  a n d  d r u g  s a f e t y  s o f t w a r e  m a r k e t  s i z e  r e a c h e d  U S $  
2 0 2 . 3  M i l l i o n  i n  2 0 2 3 .
F a c t o r s  A f fe c t i n g  t h e  Gr o w t h  o f  t h e  Ph a rma c o v i g i l a n c e  a n d  Dr u g  Sa fe t y  S o f t wa r e  
Report I n d u s t ry :
Re g u l a t o r y  Co mp l i an ce  a n d  St an d ar d s :
T h e  g r o w t h  o f  t h e  p h a r m a c o v i g i l a n c e  a n d  d r u g  s a f e t y  s o f t w a r e  i n d u s t r y  i s  h e a v i l y  i n f l u e n c e d  
Highlight and b y  s t r i n g e n t  r e g u l a t o r y  r e q u i r e m e n t s  a n d  s t a n d a r d s  s e t  b y  h e a l t h  a u t h o r i t i e s  w o r l d w i d e .  
A g e n c i e s  s u c h  a s  t h e  U . S .  F o o d  a n d  D r u g  A d m i n i s t r a t i o n  ( F D A ) ,  t h e  E u r o p e a n  M e d i c i n e s  
A g e n c y  ( E M A ) ,  a n d  t h e  W o r l d  H e a l t h  O r g a n i z a t i o n  ( W H O )  m a n d a t e  c o m p r e h e n s i v e  m o n i t o r i n g  
Description a n d  r e p o r t i n g  o f  a d v e r s e  d r u g  r e a c t i o n s  ( A D R s )  a n d  o t h e r  p h a r m a c o v i g i l a n c e  a c t i v i t i e s .  
T h e s e  r e g u l a t i o n s  n e c e s s i t a t e  t h e  i m p l e m e n t a t i o n  o f  r o b u s t  s o f t w a r e  s y s t e m s  t o  m a n a g e  a n d  
a n a l y z e  v a s t  a m o u n t s  o f  d a t a  e f f i c i e n t l y .  C o m p l i a n c e  w i t h  t h e s e  s t a n d a r d s  i s  c r i t i c a l  f o r  
p h a r m a c e u t i c a l  c o m p a n i e s  t o  a v o i d  p e n a l t i e s ,  e n s u r e  p a t i e n t  s a f e t y ,  a n d  m a i n t a i n  m a r k e t  
a p p r o v a l  f o r  t h e i r  p r o d u c t s .  C o n s e q u e n t l y ,  t h e r e  i s  a  r i s i n g  d e m a n d  f o r  a d v a n c e d  
p h a r m a c o v i g i l a n c e  s o f t w a r e  t h a t  c a n  s t r e a m l i n e  c o m p l i a n c e  p r o c e s s e s ,  a u t o m a t e  r e p o r t i n g ,  
a n d  f a c i l i t a t e  r e a l - t i m e  m o n i t o r i n g ,  d r i v i n g  i n d u s t r y  g r o w t h  a s  c o m p a n i e s  s e e k  t o  m e e t  t h e s e  
r e g u l a t o r y  c h a l l e n g e s .
Technologica l  Advancements  and Integra t ion:
Tech no log i ca l  a dvan cem e n t s  a r e  a  key  d r i ve r  o f  t h e  ph ar m a cov ig i l ance  a nd  d r ug  
sa f e t y  s o f t w a r e  i ndus t r y ' s  expan s ion .  I nno va t i ons  i n  a r t i f i c i a l  i n t e l l i gen ce  ( A I ) ,  
m ac h ine  l ea r n ing  ( M L) ,  and  b ig  da t a  a na l y t i c s  a r e  t r ans f o r m in g  t he  way  adve r se  
eve n t s  and  d r u g  s a f e t y  da t a  a r e  co l l e c t ed ,  p r oce ssed ,  an d  a na l yz ed .  A I  and  M L  
a lgo r i t hm s  ca n  i den t i f y  pa t t e r ns  and  p r ed i c t  po t en t i a l  sa f e t y  i s sue s  m o r e  ac cu r a t e l y  
Report and  f as t e r  t han  t r ad i t i ona l  m e t h ods ,  enha nc ing  t he  e f f i c i e ncy  a nd  e f f ec t i v eness  o f  
pha r m ac ov ig i l an ce  ac t i v i t i es .  
Highlight and Fur t he r m or e ,  t he  i n t eg r a t i on  o f  t hese  adv anced  t ec hno log ies  w i t h  e lec t r on ic  hea l t h  r eco r ds  ( EH Rs) ,  c l i n i ca l  t r i a l  m a nagem en t  sys t e m s  ( CTM S) ,  a nd  o t he r  hea l t hca r e  I T  
so lu t i ons  enab les  seam less  d a t a  excha nge  and  co m pr ehen s i ve  s a f e t y  m on i t o r i ng .  
Description Thes e  t echno log i ca l  en hanc em en t s  im pr ove  t he  acc u r ac y  o f  d r ug  sa f e t y  
asse ssm en t s  and  r edu ce  op e r a t io na l  c os t s  and  in c r ea se  t h e  sca lab i l i t y  o f  
pha r m ac ov ig i l an ce  op e r a t i ons ,  t hu s  f ue l i ng  t he  i nd us t r y ' s  g r o w t h .
Increas ing Volume of  Drug Development  and Cl in ica l  Tr ia ls :
The  ex pand in g  vo lum e  o f  d r ug  de ve lop m en t  a c t i v i t ie s  a nd  c l i n i ca l  t r i a ls  i s  ano t he r  
s i gn i f i can t  f ac t o r  d r i v i ng  t he  g r o w t h  o f  t he  pha r m ac ov ig i l ance  a nd  d r u g  sa f e t y  
so f t wa r e  i ndus t r y .  T he  pha r m ac eu t i ca l  i ndus t r y  i s  exp e r ien c ing  a  su r ge  i n  t he  
dev e l opm en t  o f  new  d r u gs  and  b io log ic s ,  d r i ven  by  adva nce m en t s  i n  m ed ica l  
r ese a r ch  and  b io t e chno lo gy .
Th is  inc rease  in  d rug  deve lopmen t  l eads  to  a  co r respond ing  r i se  in  c l i n i ca l  
t r ia l s ,  each  requ i r i ng  r igo rous  sa fe ty  mon i to r ing  and  adverse  even t  repor t ing .  
Pha rmacov ig i l ance  so f tware  so lu t ions  a re  essen t ia l  in  manag ing  the  comp lex  
and  la rge-sca le  da ta  genera ted  du r ing  these  t r ia l s .  They  he lp  ensure  tha t  
sa fe ty  s igna ls  a re  de tec ted  ear ly ,  and  approp r ia te  measures  a re  taken  to  
p ro tec t  t r ia l  pa r t i c ipan ts  and  fu tu re  pa t ien ts .  As  the  p ipe l ine  o f  new the rap ies  
Report grows,  the  demand  fo r  soph is t i ca ted  pharmacov ig i l ance  so f twa re  tha t  can  
hand le  the  inc reas ing  da ta  vo lume and  comp lex i t y  a lso  r i ses ,  suppor t ing  the  
indus t ry ' s  con t inuous  g rowth .
Highlight and 
Request  for  a  PDF sample  o f  th is  repor t :  
Description h t tps : / /www. imarcgroup .com/pha rmacov ig i l ance-d rug-sa fe ty -so f tware -marke t / re
ques tsamp le
Report Description
Global  Pharmacovigi lance and Drug Safety Software Market  Trends:
The g loba l  pharmacov ig i lance  and  d rug  sa fe ty  so f tware  marke t  i s  exper ienc ing  robus t  g rowth  due  to  severa l  
s ign i f i can t  t rends .  Inc reas ing  regu la to ry  requ i rements  fo r  d rug  sa fe ty  mon i to r ing  and  adve rse  even t  repo r t ing  
have  p rope l led  the  demand fo r  advanced  pha rmacov ig i l ance  so lu t ions .  Bes ides th is ,  ongo ing  techno log ica l  
advancements ,  inc lud ing  a r t i f i c ia l  in te l l igence  (A I )  and  mach ine  lea rn ing  (ML) ,  a re  enhanc ing  the  capab i l i t i es  o f  
these  so f tware  sys tems,  enab l ing  more  e f f i c ien t  da ta  ana lys i s  and  s igna l  de tec t ion .  
The  r i se  in  d rug  deve lopment  ac t iv i t ies  and  c l i n ica l  t r i a ls  g loba l ly  i s  a lso  d r i v ing  the  need  fo r  comprehens ive  
sa fe ty  mon i to r ing .  Fur the rmore ,  t he  g row ing  adop t ion  o f  c loud-based  so lu t ions  o f fe rs  sca lab i l i t y ,  f l ex ib i l i t y ,  and  
cos t -e f f i c iency ,  mak ing  pha rmacov ig i l ance  so f tware  more  access ib le  to  sma l l  and  med ium-s ized  pharmaceu t ica l  
compan ies .  Fur the rmore ,  co l l abora t ions be tween  so f tware  p rov ide rs  and  hea l thca re  o rgan iza t ions  a re  fos te r ing  
innova t ion  and  expand ing  the  marke t  reach .  
View Report  TOC,  F igures  and Tab les :  
h t tps : / /www. imarcgroup.com/pharmacovig i lance-drug-safe ty -sof tware-market
Breakup by Functionality:
• Adverse Event Report ing Software
• Drug Safety Audits  Software
• Issue Tracking Software
• Ful ly Integrated Software
Report 
Breakup by Delivery Mode:
Segmentation • On-premises
• Cloud-based
Breakup by End User:
• Pharmaceut ical  and Biotechnology Companies
• Contract  Research Organizat ions
• Business Process Outsourcing Firms
• Others
Breakup by Region:
• North America
Report • Asia-Pacifi c
Segmentation • Europe
• Latin America
• Middle East and Afr ica
• Ab Cube
• Anju Software Inc.
• ArisGlobal LLC
• Cognizant
Competitive • Ennov Solutions Inc.
• Extedo GmbH
Landscape 
• Max Appl icat ion
with Key • Oracle Corporation
Players • Sarjen Systems Pvt Ltd
• Sparta Systems Inc. (Honeywell  
International  Inc.)
• Tata Consultancy Services Limited
• United BioSource LLC
• Wipro Limited.
What was the size of the global pharmacovigilance and drug 
safety software market in 2023?
What is the expected growth rate of the global 
pharmacovigilance and drug safety software market during 
2024-2032?
What has been the impact of COVID-19 on the global 
pharmacovigilance and drug safety software market?
Key 
What are the key factors driving the global 
Questions pharmacovigilance and drug safety software market?
Answered in What is the breakup of the global pharmacovigilance and drug safety software market based on the functionality?
the Report What is the breakup of the global pharmacovigilance and 
drug safety software market based on the delivery mode?
What is the breakup of the global pharmacovigilance and 
drug safety software market based on the end user?
What are the key regions in the global pharmacovigilance 
and drug safety software market?
Who are the key players/companies in the global 
pharmacovigilance and drug safety software market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  P h a r m a c o v i g i l a n c e  a n d  D r u g  S a f e t y  S o f t w a r e  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  F u n c t i o n a l i t y
    6 . 1     A d v e r s e  E v e n t  R e p o r t i n g  S o f t w a r e
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     D r u g  S a f e t y  A u d i t s  S o f t w a r e
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     I s s u e  T r a c k i n g  S o f t w a r e
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     F u l l y  I n t e g r a t e d  S o f t w a r e
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D e l i v e r y  M o d e
    7 . 1     O n - p r e m i s e s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     C l o u d - b a s e d
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  E n d  U s e r
    8 . 1     P h a r m a c e u t i c a l  a n d  B i o t e c h n o l o g y  C o m p a n i e s
Table of         8 . 1 . 1  M a r k e t  T r e n d s        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     C o n t r a c t  R e s e a r c h  O r g a n i z a t i o n s
        8 . 2 . 1  M a r k e t  T r e n d s
Contents         8 . 2 . 2  M a r k e t  F o r e c a s t    8 . 3     B u s i n e s s  P r o c e s s  O u t s o u r c i n g  F i r m s
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
    8 . 4     O t h e r s
        8 . 4 . 1  M a r k e t  T r e n d s
        8 . 4 . 2  M a r k e t  F o r e c a s t
9    M a r k e t  B r e a k u p  b y  R e g i o n
    9 . 1     N o r t h  A m e r i c a
        9 . 1 . 1  U n i t e d  S t a t e s
           9 . 1 . 1 . 1  M a r k e t  T r e n d s
           9 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        9 . 1 . 2  C a n a d a
           9 . 1 . 2 . 1  M a r k e t  T r e n d s
           9 . 1 . 2 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / p h a rm a co v ig i l a n c e - d r u g - sa fe t y - s o f
t w a re - m a r ke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: